UK anti-trust regulator investigates S.Africa’s Aspen Pharmacare


JOHANNESBURG (Reuters) – Britain’s competition regulator has launched an investigation into Africa’s biggest generic drug maker Aspen Pharmacare over alleged anticompetitive conduct in the supply of blood pressure and arthritis drugs, Aspen said on Friday.

“The investigation is at an early, information-gathering stage and the CMA has confirmed that, at this time, it has not reached any conclusion on whether competition law has been infringed,” Aspen said in a statement.

Aspen said the drugs – Fludrocortisone acetate 0.1 mg tablets and Dexamethasone 2 mg tablets – under investigation by the UK Competition and Markets Authority (CMA) had a combined revenue of 11.1 million pounds ($15 million) in Britain last year.

Shares in Aspen, based in Durban, have surged since 2008 on the back of its overseas expansion as it benefits from the expiry of patents on best-selling drugs.

($1 = 0.7520 pounds)

Previous articleNigeria’s presidency rejects northern bias criticism over World Bank request
Next articleNigeria’s central bank governor Emefiele wins Forbes 2017 Banking Award
Godwin Okafor is a financial journalist, Internet Social Entrepreneur and the Founder Naija247news Media Ltd He has over 16 experiences in journalism, which cuts across traditional and digital media. He started his journalism career in Business Day, Where he was a senior editorial graphic artist, before he left to start Naija247news, An Online Financial Newspaper in 2010. He has won series of awards and he is the chairman of Emmerich Resources Limited, the publisher of and also sits on the board of Students In Business Awards, (SIBA).


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.